Erectile dysfunction management after failed phosphodiesterase-5-inhibitor trial: a cost-effectiveness analysis.

Area of Science:

• Urology
• Health Economics
• Decision Analysis

Background:

• Erectile dysfunction (ED) management often requires escalation after initial phosphodiesterase-5 inhibitor (PDE5-I) therapy failure.
• Evaluating the economic value of alternative ED treatments is crucial for clinical decision-making.

Purpose of the Study:

• To determine the most cost-effective ED management strategy following the failure of first-line PDE5-I treatment.
• To compare the long-term costs and quality-adjusted life years (QALYs) of various ED interventions.

Main Methods:

• A decision tree analysis model was developed using literature data and expert clinical judgment.
• The model assessed costs and QALYs for alternate PDE5-Is, intracorporal injections (ICI), and inflatable penile prosthesis (IPP) placement over a 10-year timeframe.
• Risks of treatment failure, complications (e.g., priapism), and subsequent interventions were incorporated.

Main Results:

• Inflatable penile prosthesis (IPP) placement demonstrated the highest cost-effectiveness, yielding 7.82 QALYs at a cost of $22,009 over 10 years.
• Intracorporal injections (ICI) with trimix and alprostadil were less cost-effective, with higher costs and comparable or lower QALYs.
• Alternate PDE5-I therapy was the least cost-effective option, with the lowest QALYs and high costs.

Conclusions:

• Inflatable penile prosthesis (IPP) placement is the most cost-effective intervention for erectile dysfunction (ED) after initial PDE5-I failure over a 10-year period.
• These cost-effectiveness findings support the use of IPP in counseling patients with persistent ED.
• Decision analysis provides a robust framework for evaluating complex treatment pathways in urology.